← Back to Search

Platinum Complex

BBR 3464 for Metastatic Small Cell Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by Theradex

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No other serious illness or medical condition

Histologically or cytologically confirmed metastatic small cell lung cancer (SCLC)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well BBR 3464 works in treating patients with small cell lung cancer that has spread to other parts of the body and has not responded to other treatment.

Who is the study for?

This trial is for adults with metastatic small cell lung cancer that hasn't improved after first-line chemotherapy. Participants must not have had a heart attack in the past year, uncontrolled blood pressure or arrhythmias, congestive heart failure, or angina. They should have no brain metastasis symptoms and at least one measurable lesion. Effective contraception is required if fertile.Check my eligibility

What is being tested?

The trial tests BBR 3464's effectiveness on patients with advanced small cell lung cancer who haven't responded to initial treatment. It's a Phase II study which means it focuses on the drug’s efficacy and side effects in a larger group of people than Phase I.See study design

What are the potential side effects?

While specific side effects of BBR 3464 are not listed here, common ones from similar chemotherapy drugs include nausea, fatigue, increased risk of infection due to low blood counts, hair loss, mouth sores and potential damage to organs such as the heart or kidneys.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have any serious illnesses besides my current condition.

Select...

My cancer is confirmed as metastatic small cell lung cancer.

Select...

My liver function tests are within the required limits.

Select...

My kidney function, measured by creatinine levels or clearance, meets the required standards.

Select...

My cancer did not fully respond or has returned after initial chemotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

TheradexLead Sponsor

33 Previous Clinical Trials

1,562 Total Patients Enrolled

Mark A. Socinski, MDStudy ChairUNC Lineberger Comprehensive Cancer Center

3 Previous Clinical Trials

635 Total Patients Enrolled

Media Library

BBR 3464 (Platinum Complex) Clinical Trial Eligibility Overview. Trial Name: NCT00014547 — Phase 2

Lung Cancer Clinical Trial 2023: BBR 3464 Highlights & Side Effects. Trial Name: NCT00014547 — Phase 2

BBR 3464 (Platinum Complex) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00014547 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent does this treatment present a hazard for patients?

"Our in-house assessment of the treatment's security is a 2, as this research initiative only has evidence backing its safety and cannot yet affirm efficacy."

Answered by AI

In what number of locations can this experiment be accessed?

"Currently, 18 research centres are running this clinical trial. Tulsa, Charlottesville and Chapel Hill are some of the cities that have a site available; there is also a total of 15 other locations to consider. If you plan on participating in this study it would be wise for you to pick the nearest centre to reduce your travel commitments."

Answered by AI

Is the enrollment for this trial still accepting participants?

"As per the information supplied on clinicaltrials.gov, this healthcare investigation is no longer accepting applicants - it was initially published on November 1st 2000 and its last update took place on July 23rd 2008. Currently, 1707 other trials are actively enrolling patients though."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

2000. "BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00014547.

All > Lung > Sclc